HCPCS Level IIdrugActive
J7677
Revefenacin inh non-com 1mcg
BETOS: D1G
Effective: 2019-07-01
Referenced in 2 policies
Description
Revefenacin inhalation solution, fda-approved final product, non-compounded, administered through dme, 1 microgram
Medicare Part B Drug Pricing
Average Sales Price (ASP) data for Q1 2026
Drug Name
Yupelri
Manufacturer
Viatris Specialty LLC
HCPCS Dosage
1 MCG
Billing Units
175.0000
1
NDC Products
asp
Pricing Source
Medicare Part B drugs are reimbursed at ASP + 6%. Pricing updates quarterly based on manufacturer-reported data.